Journal of Biomedical Sciences
Research Article Peer-review, Open Access

The Multifaceted Effects of SARS-Cov-2: From Respiratory Illness to Long COVID Complications

Ghambashidze Ketevan [1]

Katsadze Maia [2]

Namoradze Manana [3]

Topuridze Maka [4]

Chelidze Nana [5]

Pkhaladze Neli [6]

Abstract

SARS-CoV-2, the virus responsible for the COVID-19 pandemic, has dramatically changed the global health landscape. COVID-19 has demonstrated an unprecedented ability to cause a range of disease severities and complications, affecting nearly every organ system. Although the primary focus has been on its respiratory manifestations, it has become evident that COVID-19 can cause multisystem complications. These range from mild symptoms to severe, life-threatening conditions, even long after the acute infection. Diabetes has emerged as a major risk factor for severe COVID-19, with diabetic individuals experiencing higher rates of hospitalization, intensive care unit admission, mechanical ventilation, and mortality. Chronic hyperglycemia impairs immune function, and the virus may worsen glycemic control through its interaction with the ACE2 receptor, which is expressed in pancreatic cells. COVID-19 may lead to new-onset diabetes due to direct viral damage to pancreatic cells or stress hyperglycemia. The long-term affect of COVID-19 on global health systems remains considerable, with ongoing research critical for understanding complications, optimizing treatment protocols, and improving patient outcomes. Key areas of focus include managing comorbidities like diabetes, preventing severe complications like ARDS and thrombosis, and addressing long COVID's chronic effects. Understanding the spectrum of COVID-19 complications is crucial for improving patient management and preventing long-term health consequences. This article provides an overview of the virus's structure, transmission mechanisms, and clinical manifestations, complications and impact on global health.

Key words: SARS-CoV-2, COVID-19, complications, diabetes.

[1, 2, 3, 4, 5, 6] Tbilisi State Medical University, Tbilisi, Georgia

Introduction

Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) is the virus responsible for the global COVID-19 pandemic that began in late 2019. As part of the Coronaviridae family, SARS-CoV-2 is a highly transmissible and pathogenic virus that rapidly spread across the globe, resulting in a significant public health crisis [9]. COVID-19 is primarily transmitted through respiratory droplets or by contact with contaminated surfaces. One of the distinguishing features of SARS-CoV-2 transmission is the significant role of asymptomatic and presymptomatic carriers, which has greatly contributed to the virus's rapid and widespread transmission globally. A study published in Nature highlights that aerosol and droplet transmission were key factors in the spread of COVID-19, particularly in indoor and poorly ventilated settings [13]. Additionally, a systematic review in JAMA Network Open revealed that asymptomatic individuals were responsible for a considerable proportion of new infections, contributing to the "silent spread" of the virus [4].

The virus primarily affects the respiratory system, and severe cases often lead to acute respiratory distress syndrome (ARDS). Data from global studies indicate that ARDS affects between 15-30% of hospitalized COVID-19 patients, with mortality rates ranging from 40% to 60% in severe cases [18].

Structurally, SARS-CoV-2 is an enveloped, positive-sense single-stranded RNA virus, with a spherical shape and spike proteins on its surface. These spikes, made of spike (S) proteins, bind to host cell receptors and mediate viral entry. This structural feature is critical to its ability to infect human cells and has been a major focus of vaccine and therapeutic developments.

The spike protein (S) is essential for the virus to attach to the angiotensin-converting enzyme 2 (ACE2) receptor, which allows entry into human cells. The receptor-binding domain (RBD) of the spike protein has a high affinity for ACE2, facilitating the virus's rapid spread. Other viral proteins include the nucleocapsid protein (N), which encases viral RNA and protects it from host defenses, and the membrane (M) and envelope (E) proteins, which contribute to viral assembly and stability.

SARS-CoV-2 has undergone mutations since its emergence, leading to the development of multiple variants that have influenced the course of the pandemic. Key variants include:

- Alpha (B.1.1.7): First identified in the UK, this variant showed increased transmissibility.
- Delta (B.1.617.2): Originating in India, Delta became the dominant global variant in 2021 due to its higher transmission rate and association with more severe disease outcomes.
- Omicron (B.1.1.529): Identified in late 2021, Omicron contains numerous mutations in the spike protein, which contribute to increased transmission and immune evasion, though it generally causes less severe disease than earlier variants [9].

Although COVID-19 primarily affects the respiratory system, it is now clear that it can lead to systemic issues, impacting multiple organs. Studies have reported an increased incidence of myocarditis, heart failure, and acute coronary syndrome among COVID-19 patients. Additionally, thromboembolic events, such as pulmonary embolism, have been prominent, driven in part by the hypercoagulable state induced by the virus [18].

A growing body of research highlights neurological sequelae in COVID-19 patients, ranging from mild cognitive dysfunction and anosmia to more severe conditions like stroke, encephalopathy, and Guillain-Barré syndrome. A study published in Lancet Neurology noted that up to 30% of hospitalized COVID-19 patients experienced neurological symptoms, with strokes occurring in approximately 1.5-6% of hospitalized patients [9]. Moreover, acute kidney injury (AKI) has emerged as a severe complication, particularly in critically ill patients, with studies suggesting that AKI occurs in 20-40% of hospitalized cases. A study in Kidney International showed that AKI is associated with increased mortality, particularly in patients requiring renal replacement therapy [18].

SARS-CoV-2 enters cells via the ACE2 receptor, which is expressed in various tissues, including the

lungs, heart, kidneys, and gastrointestinal tract. This widespread expression of ACE2 explains why the virus can cause multi-organ damage. In addition, the immune system's dysregulated response, characterized by an excessive inflammatory reaction known as a cytokine storm, is often responsible for severe complications, including ARDS and multi-organ failure [9].

SARS-CoV-2 primarily targets the epithelial cells in the respiratory tract, leading to viral replication and infection. The clinical manifestation of COVID-19 varies widely, ranging from mild symptoms to severe viral pneumonia, acute respiratory distress syndrome (ARDS), and multi-organ failure. In severe cases, an excessive immune response, known as a cytokine storm, can occur, causing significant damage [12]. This hyperinflammatory response is responsible for much of the severe pathology seen in critically ill patients, including ARDS, multi-organ failure, and even death [7].

The clinical spectrum of COVID-19 includes a wide array of symptoms. Mild to moderate cases are often characterized by fever, cough, fatigue, and difficulty breathing. However, more severe cases can progress to ARDS, septic shock, and death, particularly in older adults and those with pre-existing conditions such as cardiovascular disease, hypertension, and diabetes [18]. A large-scale study on COVID-19 patients from Wuhan, China, published in The Lancet, found that fever (88%), cough (68%), and fatigue (38%) were the most common presenting symptoms [9]. Data from a cohort study in The New England Journal of Medicine further emphasized that older adults and individuals with comorbidities like obesity, diabetes, and hypertension were at increased risk for severe outcomes, including hospitalization and death [8].

One of the most perplexing aspects of COVID-19 is the persistence of symptoms long after the acute infection, a condition commonly referred to as "Long COVID" or Post-Acute Sequelae of SARS-CoV-2 Infection (PASC) [14]. Long COVID symptoms, such as fatigue, shortness of breath, cognitive dysfunction (often referred to as "brain fog"), and joint pain, can persist for months. A longitudinal study published in JAMA reported that around 30% of patients experienced ongoing symptoms six months after their initial infection, even in cases where the acute illness was mild [11].

Diabetes has emerged as a significant comorbidity associated with severe COVID-19 outcomes. Individuals with diabetes not only face a higher susceptibility to contracting the virus but also experience more severe complications, including hospitalization, the need for mechanical ventilation, and higher mortality rates [3]. The bidirectional relationship between diabetes and COVID-19 underscores the importance of understanding how SARS-CoV-2 impacts metabolic health and how diabetes can exacerbate the disease's outcomes [2].

The mechanisms that contribute to the increased susceptibility of people with diabetes to severe COVID-19 are complex:

- **Hyperglycemia and Immune Dysfunction**: Chronic hyperglycemia in diabetes impairs immune cell function, including neutrophils, macrophages, and lymphocytes, reducing the body's ability to combat infections like SARS-CoV-2 [17].
- **Cytokine Storm and Inflammation**: Individuals with diabetes tend to have higher baseline levels of inflammatory cytokines, such as interleukin-6 (IL-6). When infected with SARS-CoV-2, this pre-existing inflammation can trigger a more severe cytokine storm, worsening ARDS and multi-organ damage [5].
- **ACE2 Expression**: The ACE2 receptor, which SARS-CoV-2 uses to enter cells, is expressed in pancreatic β-cells. This raises the possibility that the virus could directly impair insulin secretion, worsening glycemic control in diabetic patients [16].

Diabetes has consistently been shown to be a significant risk factor for more severe illness in COVID-19. Studies from across the globe have demonstrated that individuals with diabetes are more likely to experience severe complications, require intensive care, and have higher mortality rates. For example, a large cohort study from China found that individuals with diabetes had significantly higher mortality

rates, with hyperglycemia exacerbating the inflammatory and pro-thrombotic responses to COVID-19 [18]. Similarly, a meta-analysis published in Diabetes Care reported that individuals with diabetes had an approximately two-fold increased risk of death from COVID-19 compared to those without diabetes, with this risk being even higher among those with poorly controlled blood sugar levels [10].

Data from the Centers for Disease Control and Prevention (CDC) and large cohort studies also indicate that individuals with diabetes are more likely to require hospitalization, with many needing ICU-level care and mechanical ventilation. This is especially pronounced in patients with Type 2 diabetes, who often have additional comorbidities such as hypertension and obesity, which further complicate their clinical outcomes [8].

An emerging concern is the association of COVID-19 with new-onset diabetes. Some individuals, particularly those who experienced severe illness, have been diagnosed with diabetes following their COVID-19 infection. While the exact mechanisms remain under investigation, several hypotheses have emerged:

- **Direct Impact on Pancreatic Cells**: SARS-CoV-2 may infect pancreatic β-cells through the ACE2 receptor, leading to β-cell destruction or dysfunction, impairing insulin production [16].
- **Stress Hyperglycemia**: Severe illness, including COVID-19, can lead to stress hyperglycemia. In some cases, this acute hyperglycemia may reveal underlying pre-diabetes or predispose individuals to developing diabetes after recovery [6].
- **Inflammation-Induced Insulin Resistance**: The systemic inflammation associated with COVID-19 can trigger insulin resistance, particularly in individuals with pre-existing metabolic risk factors such as obesity or pre-diabetes [3].

Long COVID, or post-acute sequelae of SARS-CoV-2 infection (PASC), has been widely reported among individuals recovering from COVID-19, including those with pre-existing diabetes. Diabetic individuals are at an elevated risk of experiencing prolonged symptoms such as fatigue, dyspnea, and cognitive difficulties like "brain fog." Research suggests that individuals with diabetes may be more susceptible to these prolonged symptoms due to the underlying chronic inflammation and immune dysfunction associated with diabetes [1].

Moreover, evidence suggests that the pandemic has indirectly contributed to the worsening of glycemic control in individuals with pre-existing diabetes. Lockdowns, restrictions on movement, and disruption of routine healthcare services have all played a role in this. A survey conducted by the International Diabetes Federation (IDF) found that a significant percentage of individuals with diabetes reported difficulty accessing medications, blood glucose testing supplies, and routine check-ups during the pandemic [15]. This lack of access, combined with stress and changes in lifestyle, has exacerbated diabetes management and may have long-term implications for public health.

Conclusion. Analysis of the literature and clinical data reveals several key findings:

ARDS remains one of the most common severe complications, particularly in patients with underlying health conditions such as diabetes, obesity, and hypertension.

Cardiovascular complications, especially thrombosis, have necessitated widespread use of anticoagulation therapy in COVID-19 treatment protocols. Early intervention with anticoagulants has been shown to reduce the risk of thromboembolic events and improve outcomes in critically ill patients.

Neurological symptoms are more frequent than initially suspected, with both mild and severe effects seen across age groups. Although long-term neurological impacts remain under study, strokes and cognitive impairment are alarming concerns.

Renal failure and the onset of acute kidney injury are strongly associated with higher mortality rates, particularly in critically ill patients who require mechanical ventilation or extracorporeal membrane

oxygenation.

Diabetes has emerged as one of the most significant comorbidities associated with severe outcomes in patients with COVID-19. Individuals with diabetes are not only more susceptible to contracting the virus but are also significantly increases the risk of severe outcomes in COVID-19, including higher rates of hospitalization, complications, and mortality. Proper management of blood glucose during infection is crucial for improving outcomes. The link between COVID-19 and new-onset diabetes highlights the complexity of the virus's interaction with metabolic health.

Continued research is needed to understand the long-term effects of COVID-19 on individuals with diabetes and to develop strategies for managing these patients during the pandemic and beyond. The relationship between diabetes and COVID-19 underscores the importance of understanding how SARS-CoV-2 impacts metabolic health and how diabetes can worsen COVID-19 outcomes.

The long-Covid on global health systems remains considerable. Continued research is critical to fully understand the mechanisms of these complications, optimize treatment protocols, and improve acute and long-term patient outcomes.

References

1. Al-Aly, Z., Xie, Y., & Bowe, B. (2021). Long COVID after breakthrough SARS-CoV-2 infection. Nature Medicine, 27(4), 1-4. https://doi.org/10.1038/s41591-021-01494-2
2. Apicella, M., Campopiano, M. C., Mantuano, M., et al. (2020). COVID-19 in people with diabetes: understanding the reasons for worse outcomes. The Lancet Diabetes & Endocrinology, 8(5), 382-392. https://doi.org/10.1016/S2213-8587(20)30109-5
3. Bornstein, S. R., Rubino, F., & Kahleova, H. (2020). The COVID-19 pandemic and diabetes: the impact of diabetes on COVID-19 outcomes. Diabetes Care, 43(8), 1680-1690. https://doi.org/10.2337/dc20-0818
4. Buitrago-Garcia, D. C., Egli-Gany, D., & Imeri, H. (2020). Asymptomatic transmission of SARS-CoV-2: a systematic review and meta-analysis. JAMA Network Open, 3(12), e2035057. https://doi.org/10.1001/jamanetworkopen.2020.35057
5. Cao, Y. (2020). Inflammation and COVID-19: the role of cytokines. Nature Reviews Immunology, 20(7), 430-431. https://doi.org/10.1038/s41577-020-0375-6
6. Cui, Y., Tian, M., Huang, D., et al. (2020). Diabetes is associated with the severity and mortality of COVID-19: A systematic review and meta-analysis. Diabetes Research and Clinical Practice, 166, 108338. https://doi.org/10.1016/j.diabres.2020.108338
7. Fajgenbaum, D. C., & June, C. H. (2020). Cytokine Storm. The New England Journal of Medicine, 383(23), 2259-2270. https://doi.org/10.1056/NEJMsr2020027
8. Guan, W. J., Ni, Z. Y., Hu, Y., et al. (2020). Clinical characteristics of coronavirus disease 2019 in China. The New England Journal of Medicine, 382(18), 1708-1720. https://doi.org/10.1056/NEJMoa2002032
9. Huang, C., Wang, Y., Li, X., et al. (2020). Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. The Lancet, 395(10223), 497-506. https://doi.org/10.1016/S0140-6736(20)30183-5
10. Huang, Y., & Zhao, M. (2021). Diabetes and COVID-19: A narrative review. Diabetes Research and Clinical Practice, 170, 108490. https://doi.org/10.1016/j.diabres.2020.108490
11. Logue, J. K., Franko, N. M., & Delayed, T. (2021). Sequelae in Adults at 6 Months After COVID-19 Infection. JAMA Network Open, 4(2), e210830. https://doi.org/10.1001/jamanetworkopen.2021.0830

12. Merad, M., & Martin, J. C. (2020). Pathological inflammation in patients with COVID-19: a key to understanding severity. Nature Reviews Immunology, 20(5), 285-286. https://doi.org/10.1038/s41577-020-0304-5
13. Morawska, L., & Cao, J. (2020). Airborne transmission of SARS-CoV-2: The world should face the reality. Environmental International, 139, 105730. https://doi.org/10.1016/j.envint.2020.105730
14. Nalbandian, A., et al. (2021). Post-acute sequelae of SARS-CoV-2 infection: A state-of-the-art review. JAMA Network Open, 4(1), e210301. https://doi.org/10.1001/jamanetworkopen.2021.0301
15. Rubino, F., & Amiel, S. A. (2020). New-Onset Diabetes in Covid-19. Diabetes Care, 43(12), 2661-2667. https://doi.org/10.2337/dc20-1778
16. Yang, J., et al. (2020). ACE2 expression in pancreatic β-cells increases the risk of COVID-19. Diabetes Care, 43(7), e106-e107. https://doi.org/10.2337/dc20-0810
17. Zhu, L., et al. (2020). Association of Blood Glucose Control and Clinical Outcomes in Patients with COVID-19 and Preexisting Diabetes. Diabetes Care, 43(7), 1640-1647. https://doi.org/10.2337/dc20-0792
18. Zhou, F., Yu, T., Du, R., et al. (2020). Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. The Lancet, 395(10229), 1054-1062. https://doi.org/10.1016/S0140-6736(20)30566-3